Heartflow, Inc. (NASDAQ:HTFL) Given Average Rating of "Moderate Buy" by Brokerages

Key Points

• Heartflow, Inc. (NASDAQ:HTFL) has received a consensus rating of "Moderate Buy" from analysts, with one hold and four buy recommendations.
• The average twelve-month price target for Heartflow among brokerages is $35.80, with several analysts setting targets between $35.00 and $38.00.
• Heartflow's stock opened at $31.50, representing a 12-month range between $26.56 and $36.68.

Shares of Heartflow, Inc. (NASDAQ:HTFL - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six research firms that are covering the company, MarketBeat Ratings reports. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $35.80.

A number of equities analysts have recently issued reports on HTFL shares. JPMorgan Chase & Co. started coverage on shares of Heartflow in a research report on Tuesday. They set an "overweight" rating and a $36.00 target price on the stock. Zacks Research upgraded shares of Heartflow to a "hold" rating in a research report on Wednesday. Piper Sandler started coverage on shares of Heartflow in a research report on Tuesday. They set an "overweight" rating and a $38.00 target price on the stock. Canaccord Genuity Group began coverage on shares of Heartflow in a research report on Tuesday. They set a "buy" rating and a $35.00 target price on the stock. Finally, Morgan Stanley began coverage on Heartflow in a report on Tuesday. They set an "equal weight" rating and a $35.00 price target for the company.

Heartflow Trading Down 8.8%

Heartflow stock traded down $3.01 during mid-day trading on Tuesday, hitting $31.07. The company had a trading volume of 442,043 shares, compared to its average volume of 878,154. Heartflow has a 1 year low of $26.56 and a 1 year high of $36.68.

Heartflow Company Profile

We have pioneered the use of software and AI to deliver a more accurate and clinically effective non-invasive solution for diagnosing and managing coronary artery disease (“CAD”), a leading cause of death worldwide. As of March 31, 2025, our Heartflow Platform has been used to assess CAD in more than 400,000 patients, including 132,000 in 2024 alone.